Supplementation with 18 downregulated the protein expression of iNOS, NF-κB, p-IκBα, IKKα and COX-2, reinforcing the contribution of nimbolide to the therapeutic strategy against RA [99]. The gene discussed is PTGS2; the disease is rheumatoid arthritis.